معرفی
Professor Ghazaleh Tabatabai serves as Head of Department for Clinical and Experimental Neuro-Oncology at the Hertie Institute for Clinical Brain Research, University of Tübingen. She leads a multidisciplinary research group focused on translational neuro-oncology with active collaborations through the German Glioma Network, German Cancer Consortium (DKTK), European Organisation for Research and Treatment of Cancer (EORTC), European Association of Neuro-Oncology (EANO), and International Consortium on Meningioma (ICOM).
Her research program centers on molecular mechanisms of tumorigenesis, therapy resistance, and treatment-induced vulnerabilities in nervous system tumors. The laboratory employs CRISPR screening technologies, molecular profiling, and preclinical models to identify therapeutic targets, with particular expertise in glioma and meningioma biology. Current projects span from discovery through validation to clinical application, including phase I/II trials of novel therapies such as CureVac's mRNA vaccine candidate CVGBM.
Recent publications demonstrate leadership in molecular classification of meningiomas, CRISPR-based target discovery, immunotherapy development, and clinical trial design. Her work on the TRACE app for patient-reported outcomes and the PRIDE trial for dose-escalated radiation therapy represents significant clinical translation efforts. The 2024-2025 publication record shows strong productivity with high-impact papers in Neuro-Oncology, Nature Medicine, and Genome Biology.
- Elected spokesperson of the DFG Board for Neuroscience (2024)
- Active participation in EANO guideline development
- Leadership in multiple international consortia including ICOM
- Principal investigator for clinical trials including N2M2/NOA-20 umbrella trial
Professor Tabatabai mentors a large research team including PhD students, medical doctoral candidates, and postdoctoral researchers. Her laboratory maintains active clinical collaborations across neurosurgery, radiation oncology, and medical oncology departments. She is featured in the 'Key To My Research' podcast discussing tumor intelligence and regularly presents at major neuro-oncology conferences including ASCO, EANO, and SNO.
